Skip to main content

Quest Diagnostics Value Stock - Dividend - Research Selection

Quest diagnostics

ISIN: US74834L1008 , WKN: 904533

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company\'s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Here's How Quest Diagnostics Is Placed Ahead of Q4 Earnings

2026-02-06
DGX heads into Q4 earnings with expected revenue and EPS growth, DIS momentum, and benefits from Fresenius assets and consumer testing.

Cleveland Diagnostics Names Jack Kenny as Chairman of the Board

2026-02-05
CLEVELAND, February 05, 2026--Cleveland Diagnostics Names Jack Kenny as Chairman of the Board

Is Contineum Therapeutics, Inc. (CTNM) Stock Outpacing Its Medical Peers This Year?

2026-02-04
Here is how Contineum Therapeutics, Inc. (CTNM) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.

Is Quest Diagnostics (DGX) Still Attractive After Recent Share Price Strength?

2026-02-04
If you have been wondering whether Quest Diagnostics at around US$185 per share is a fair deal or a stretch, you are not alone. The stock has returned 0.5% over the last 7 days, 6.5% over the past month and year to date, 15.5% over 1 year, 34.8% over 3 years, and 67.7% over 5 years, which naturally raises questions about how that lines up with its underlying value. Recent attention on Quest Diagnostics has centered on its role as a large player in medical testing and diagnostics, as...

DaVita Stock Up Following Q4 Earnings & Revenue Beat, Margins Expand

2026-02-03
DVA reports a fourth-quarter 2025 earnings and revenue beat as margins expanded and full-year adjusted EPS rose by double digits.

In response to private lab closure in Sudbury, experts call on the province to transfer the service back to local public hospitals

2026-02-03
SUDBURY, Ontario, Feb. 03, 2026 (GLOBE NEWSWIRE) -- In response to the revelation that Lifelabs is closing its Sudbury laboratory, the Ontario Health Coalition called on the province to restore outpatient lab testing in the local public hospitals. The Coalition noted that Lifelabs is a profitable company and was bought last year by Quest Diagnostics, which projected 2025 year end net revenues of almost $11 billion. This is the latest in the consolidation of the for-profit “market” for community

Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease

2026-02-02
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel blood test that uses advanced flow cytometry methods to assess measurable residual disease (MRD) in patients with the blood cancer myeloma (also called multiple myeloma). Called Quest Flow Cytometry MRD for Myeloma, the new test provides comparable sensitivity as next-generation sequencing methods in detecting residual myeloma*, but at a fraction of the cost, supporting bet

Coca-Cola, Pepsi Among 19 Companies To Announce Annual Dividend Increases In First Half Of February

2026-02-02
February dividend outlook: Coca-Cola, Pepsi and 19 growers likely raise payouts 3–5%.

Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls

2026-01-30
Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls

Quest Diagnostics: A Continuing Bullish Case For A Leader Among Diagnostic Testing Brands

2026-01-28